JP4571408B2 - 癌治療薬としての、s−ジメチルアルシノ−チオコハク酸、s−ジメチルアルシノ−2−チオ安息香酸、s−(ジメチルアルシノ)グルタチオン - Google Patents

癌治療薬としての、s−ジメチルアルシノ−チオコハク酸、s−ジメチルアルシノ−2−チオ安息香酸、s−(ジメチルアルシノ)グルタチオン Download PDF

Info

Publication number
JP4571408B2
JP4571408B2 JP2003557380A JP2003557380A JP4571408B2 JP 4571408 B2 JP4571408 B2 JP 4571408B2 JP 2003557380 A JP2003557380 A JP 2003557380A JP 2003557380 A JP2003557380 A JP 2003557380A JP 4571408 B2 JP4571408 B2 JP 4571408B2
Authority
JP
Japan
Prior art keywords
cancer
use according
cooh
compound
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
JP2003557380A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005527487A (ja
JP2005527487A5 (US07981874-20110719-C00313.png
Inventor
ラルフ エー. ジンガロ
エミール エル. フライライヒ
ヘイチス デュケイル
アゴプ カンタルジャン
スルジャン ベルストフセク
メリンダ ソテロ−レルマ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Texas System
Original Assignee
University of Texas System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Texas System filed Critical University of Texas System
Publication of JP2005527487A publication Critical patent/JP2005527487A/ja
Publication of JP2005527487A5 publication Critical patent/JP2005527487A5/ja
Application granted granted Critical
Publication of JP4571408B2 publication Critical patent/JP4571408B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/66Arsenic compounds
    • C07F9/70Organo-arsenic compounds
    • C07F9/72Aliphatic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2003557380A 2002-01-07 2003-01-07 癌治療薬としての、s−ジメチルアルシノ−チオコハク酸、s−ジメチルアルシノ−2−チオ安息香酸、s−(ジメチルアルシノ)グルタチオン Expired - Lifetime JP4571408B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US34649202P 2002-01-07 2002-01-07
PCT/US2003/000281 WO2003057012A2 (en) 2002-01-07 2003-01-07 S-dimethylarsino-thiosuccinic acid s-dimethylarsino-2-thiobenzoic acid s-(dimethylarsino) glutathione as treatments for cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2009279362A Division JP5603593B2 (ja) 2002-01-07 2009-12-09 癌治療薬としての、s−ジメチルアルシノ−チオコハク酸、s−ジメチルアルシノ−2−チオ安息香酸、s−(ジメチルアルシノ)グルタチオン

Publications (3)

Publication Number Publication Date
JP2005527487A JP2005527487A (ja) 2005-09-15
JP2005527487A5 JP2005527487A5 (US07981874-20110719-C00313.png) 2006-08-17
JP4571408B2 true JP4571408B2 (ja) 2010-10-27

Family

ID=23359639

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2003557380A Expired - Lifetime JP4571408B2 (ja) 2002-01-07 2003-01-07 癌治療薬としての、s−ジメチルアルシノ−チオコハク酸、s−ジメチルアルシノ−2−チオ安息香酸、s−(ジメチルアルシノ)グルタチオン
JP2009279362A Expired - Fee Related JP5603593B2 (ja) 2002-01-07 2009-12-09 癌治療薬としての、s−ジメチルアルシノ−チオコハク酸、s−ジメチルアルシノ−2−チオ安息香酸、s−(ジメチルアルシノ)グルタチオン
JP2013172071A Pending JP2013237701A (ja) 2002-01-07 2013-08-22 癌治療薬としての、s−ジメチルアルシノ−チオコハク酸、s−ジメチルアルシノ−2−チオ安息香酸、s−(ジメチルアルシノ)グルタチオン
JP2015051753A Pending JP2015120745A (ja) 2002-01-07 2015-03-16 癌治療薬としての、s−ジメチルアルシノ−チオコハク酸、s−ジメチルアルシノ−2−チオ安息香酸、s−(ジメチルアルシノ)グルタチオン

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2009279362A Expired - Fee Related JP5603593B2 (ja) 2002-01-07 2009-12-09 癌治療薬としての、s−ジメチルアルシノ−チオコハク酸、s−ジメチルアルシノ−2−チオ安息香酸、s−(ジメチルアルシノ)グルタチオン
JP2013172071A Pending JP2013237701A (ja) 2002-01-07 2013-08-22 癌治療薬としての、s−ジメチルアルシノ−チオコハク酸、s−ジメチルアルシノ−2−チオ安息香酸、s−(ジメチルアルシノ)グルタチオン
JP2015051753A Pending JP2015120745A (ja) 2002-01-07 2015-03-16 癌治療薬としての、s−ジメチルアルシノ−チオコハク酸、s−ジメチルアルシノ−2−チオ安息香酸、s−(ジメチルアルシノ)グルタチオン

Country Status (6)

Country Link
US (4) US6911471B2 (US07981874-20110719-C00313.png)
EP (3) EP2462932A1 (US07981874-20110719-C00313.png)
JP (4) JP4571408B2 (US07981874-20110719-C00313.png)
AU (1) AU2003207455B2 (US07981874-20110719-C00313.png)
CA (1) CA2472633C (US07981874-20110719-C00313.png)
WO (1) WO2003057012A2 (US07981874-20110719-C00313.png)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4571408B2 (ja) * 2002-01-07 2010-10-27 ボード・オブ・リージエンツ,ザ・ユニバーシテイ・オブ・テキサス・システム 癌治療薬としての、s−ジメチルアルシノ−チオコハク酸、s−ジメチルアルシノ−2−チオ安息香酸、s−(ジメチルアルシノ)グルタチオン
AU2011204901B2 (en) * 2004-07-16 2013-09-12 Board Of Regents, The University Of Texas System Compounds and methods for treatment of cancer
TWI411431B (zh) * 2004-07-16 2013-10-11 Texas A & M Univ Sys 有機砷化合物、其用於治療癌症之用途及包含其之醫藥組成物
EP2394702B1 (en) * 2005-07-29 2014-12-31 Ziopharm Oncology, Inc. Compounds and methods for the treatment of cancer
WO2007082104A2 (en) * 2006-01-13 2007-07-19 The Texas A & M University System Compounds and methods for the treatment of cancer
TW200829261A (en) * 2006-09-29 2008-07-16 Ziopharm Oncology Inc Method for controlling angiogenesis in animals
JP5301449B2 (ja) * 2006-11-01 2013-09-25 ニューサウス イノベイションズ ピーティーワイ リミテッド 有機アルセノキシド化合物およびその使用
KR20100100835A (ko) * 2007-11-02 2010-09-15 지오팜 온콜로지 인코포레이티드 유기 비소제와의 병용 요법
CN104592302A (zh) * 2007-12-12 2015-05-06 日本苏爱康制药有限公司 用于治疗癌症的化合物和方法
BRPI0912175A2 (pt) * 2008-05-28 2015-10-06 Basf Se métodos para diagnosticar indução de enzima do fígado, para determinar se um composto é capaz de induzir indução de enzima do fígado em um indivíduo, e para identificar uma substância para tratar indução de enzima do fígado
EP2321012B1 (en) 2008-08-20 2018-10-10 Solasia Pharma K.K. Organoarsenic compounds and methods for the treatment of cancer
CA2800260C (en) * 2010-04-19 2013-07-09 Sri International Compositions and method for the treatment of multiple myeloma
CN105899486A (zh) * 2013-12-05 2016-08-24 日本苏爱康制药有限公司 用于治疗癌症的化合物和方法
CN112941027B (zh) * 2021-03-19 2021-11-02 苏州大学 二甲基亚胂酸致人角质形成细胞恶性转化细胞株及其应用

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2349729A (en) * 1940-08-24 1944-05-23 Parke Davis & Co Therapeutic arsenic preparation
US2701812A (en) * 1951-06-26 1955-02-08 Dainippon Pharmaceutical Co Diarylarsenious acid derivatives and the preparation thereof
DE3229565A1 (de) * 1982-08-07 1984-02-16 Etschenberg, Eugen, Dr., 5000 Köln Arsenhaltige nucleoside
FR2640269B1 (fr) * 1988-12-13 1991-03-15 Maes Ludo Composes organometalliques, leurs modes de preparation et compositions pharmaceutiques les contenant
US6875451B2 (en) 1997-10-15 2005-04-05 Polarx Biopharmaceuticals Inc. Compositions and methods for the treatment of primary and metastatic neoplastic diseases using arsenic compounds
PL343868A1 (en) 1997-11-10 2001-09-10 Sloan Kettering Inst Cancer Process for producing arsenic trioxide formulations and methods for treating cancer using arsenic trioxide or melarsoprol
CN1233476A (zh) * 1998-04-24 1999-11-03 陆道培 治疗急性白血病的药物及其制备方法
EP1002537A1 (en) 1998-10-30 2000-05-24 Assistance Publique, Hopitaux De Paris Use of melarsoprol for the manufacture of a medicament for treating B-cell lymphoproliferative diseases, such as multiple myeloma
US6191123B1 (en) 1999-03-19 2001-02-20 Parker Hughes Institute Organic-arsenic compounds
AUPQ296799A0 (en) * 1999-09-20 1999-10-14 Unisearch Limited A cell-membrane impermeable trivalent organoarsenical derivative and use thereof
DE60118172T2 (de) 2000-04-26 2007-03-08 Oregon Health Sciences University, Portland Verabreichung von einer chemoschützenden verbindung,welche eine thiolgruppe enthält
AUPR379801A0 (en) 2001-03-19 2001-04-12 Unisearch Limited Use of a substantially cell membrane impermeable compound for treating arthritis
AUPR598901A0 (en) 2001-06-28 2001-07-19 Unisearch Limited Inhibition of angiogenesis by targeting protein tyrosine phosphatases
CA2417008A1 (en) 2001-07-06 2003-01-16 Cochlear Limited Configuration of implanted devices
JP4571408B2 (ja) * 2002-01-07 2010-10-27 ボード・オブ・リージエンツ,ザ・ユニバーシテイ・オブ・テキサス・システム 癌治療薬としての、s−ジメチルアルシノ−チオコハク酸、s−ジメチルアルシノ−2−チオ安息香酸、s−(ジメチルアルシノ)グルタチオン
ES2330519T3 (es) 2002-11-07 2009-12-11 Newsouth Innovations Pty Limited Inducion de la transicion de permeabilidad mitocondrial.
TWI411431B (zh) 2004-07-16 2013-10-11 Texas A & M Univ Sys 有機砷化合物、其用於治療癌症之用途及包含其之醫藥組成物
JP5301449B2 (ja) 2006-11-01 2013-09-25 ニューサウス イノベイションズ ピーティーワイ リミテッド 有機アルセノキシド化合物およびその使用

Also Published As

Publication number Publication date
WO2003057012A8 (en) 2004-04-01
AU2003207455B2 (en) 2007-09-20
JP2013237701A (ja) 2013-11-28
JP2005527487A (ja) 2005-09-15
EP2462932A1 (en) 2012-06-13
JP2015120745A (ja) 2015-07-02
US6995188B2 (en) 2006-02-07
AU2003207455A1 (en) 2003-07-24
US20040034095A1 (en) 2004-02-19
US20050131062A1 (en) 2005-06-16
EP1474128A4 (en) 2006-05-03
US20080090904A1 (en) 2008-04-17
EP2420229A1 (en) 2012-02-22
AU2003207455A2 (en) 2003-07-24
EP1474128A2 (en) 2004-11-10
WO2003057012A2 (en) 2003-07-17
JP2010090149A (ja) 2010-04-22
US7619000B2 (en) 2009-11-17
EP1474128B1 (en) 2016-06-01
JP5603593B2 (ja) 2014-10-08
US20060189687A1 (en) 2006-08-24
CA2472633C (en) 2014-07-08
CA2472633A1 (en) 2003-07-17
US6911471B2 (en) 2005-06-28
WO2003057012A3 (en) 2004-07-08

Similar Documents

Publication Publication Date Title
JP5603593B2 (ja) 癌治療薬としての、s−ジメチルアルシノ−チオコハク酸、s−ジメチルアルシノ−2−チオ安息香酸、s−(ジメチルアルシノ)グルタチオン
JP5745660B2 (ja) 癌の治療のための化合物および方法
AU2007249110C1 (en) S-dimethylarsino-thiosuccinic acid S-dimethylarsino-2-thiobenzoic acid S-(dimethylarsino) glutathione as treatment for cancer
AU2011204901B2 (en) Compounds and methods for treatment of cancer

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20060106

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060630

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20090209

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090611

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20090821

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20090828

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20091209

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100310

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100513

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20100721

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20100812

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20130820

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Ref document number: 4571408

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R153 Grant of patent term extension

Free format text: JAPANESE INTERMEDIATE CODE: R153

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250